VIDEO: Choice of biologic ‘not an easy task’ in severe asthma

In this Healio video exclusive, Nicola A. Hanania, MD, MS, discusses a CHEST Annual Meeting symposium in which he participated that addressed choice of biologic in severe asthma.

“Choice of biologic is not an easy task because there are six of them approved in the United States for severe asthma, and clinicians who treat severe asthma have to decide which one to choose,” Hanania, professor of medicine and director of the Airways Clinical Research Center at Baylor College of Medicine, told Healio.

Hanania, who is also the clinical sciences representative for the Baylor College of Medicine Faculty Senate, presented data on the dosing of omalizumab in moderate to severe allergic asthma and the effect on exacerbations and hospitalizations within 1 year of initiating treatment.

“Omalizumab was highlighted as a biologic that’s been there for more than 18 years, and it targets allergic asthma, and so an allergic phenotype is important in choosing this drug,” he said.

Reference:

Hanania NA. Reductions in exacerbations and hospitalizations are similar across different omalizumab dosing regimens. Presented at: CHEST Annual Meeting; Oct. 16-19, 2022; Nashville, Tennessee.

For more information:

Nicola A. Hanania, MD, MS, can be reached on Twitter: @Hananianick.